Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Stephen Lim"'
Autor:
Armando Sanchez, Robert Vescio, Shahrooz Eshaghian, Daisy Martinez, Tanya M. Spektor, James R. Berenson, Regina A. Swift, Robert A. Moss, Laura Stampleman, Jennifer To, Stephen Lim, Benjamin Eades, Matthew Ghermezi, Gary T. Schwartz, Carley Turner
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(10)
Purpose: Ruxolitinib with lenalidomide and dexamethasone shows antimyeloma effects in vitro and in vivo. MUC1 leads to lenalidomide resistance in multiple myeloma cells, and ruxolitinib blocks its expression. Thus, ruxolitinib may restore sensitivity
Autor:
Honghao Hank Yang, Robert Vescio, Stephen Lim, James R. Berenson, Tanya M. Spektor, Benjamin Eades, Gary T. Schwartz, Armando Sanchez, Daisy Martinez, Eli Forouzan, Jennifer To, Noemi Silagan, Shahrooz Eshaghian, Ralph V. Boccia, Regina A. Swift
Publikováno v:
Blood. 136:36-36
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with intermediate or high-risk myelofibrosis and polycythemia vera who have had an inadequate response to or are intol
Autor:
Youram Nassir, Alberto Bessudo, Gary T. Schwartz, Benjamin Eades, Robert Vescio, Carley Turner, James R. Berenson, Matthew Ghermezi, Laura Stampleman, Armando Sanchez, Tanya M. Spektor, Jennifer To, Stephen Lim, Shahrooz Eshaghian, Robert A. Moss, Daisy Martinez, Regina A. Swift, Ravindranath Patel
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e249
Autor:
Carley Turner, Laura Stampleman, Armando Sanchez, Shahrooz Eshaghian, Robert A. Moss, Ravindranath Patel, Youram Nassir, Stephen Lim, Gary T. Schwartz, Benjamin Eades, Jennifer To, Daisy Martinez, Robert Vescio, Tanya M. Spektor, Matthew Ghermezi, Regina A. Swift, James R. Berenson, Alberto Bessudo
Publikováno v:
Journal of Clinical Oncology. 37:8048-8048
8048 Background: Preclinical studies from our laboratory have demonstrated that ruxolitinib (RUX) in combination with lenalidomide (LEN) and dexamethasone shows marked anti-myeloma effects both in vitro and in vivo. Furthermore, MUC1 is responsible f
Autor:
To Jennifer, Ravindranath Patel, Shahrooz Eshaghian, Carley Turner, Gary T. Schwartz, Stephen Lim, Alberto Bessudo, Robert A. Moss, Benjamin Eades, Laura Stampleman, Robert Vescio, Tanya M. Spektor, Regina A. Swift, James R. Berenson
Publikováno v:
Blood. 132:1988-1988
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea or intermediate or high
Autor:
Regina A. Swift, Robert Vescio, James R. Berenson, Robert A. Moss, Jennifer To, Tanya M. Spektor, Stephen Lim, Benjamin Eades, Gary T. Schwartz, Carley Turner, Shahrooz Eshaghian, Laura Stampleman
Publikováno v:
Journal of Clinical Oncology. 36:8005-8005
8005Background: Preclinical studies from our laboratory have demonstrated that ruxolitinib (RUX) in combination with lenalidomide (LEN) and dexamethasone shows marked anti-myeloma effects both in vitro and in vivo. Furthermore, MUC1 is responsible fo